dc.contributor.author
Kurreck, Annika
dc.contributor.author
Gronau, Felix
dc.contributor.author
Vilchez, Miguel Enrique Alberto
dc.contributor.author
Abels, Wiltrud
dc.contributor.author
Enghard, Philipp
dc.contributor.author
Brandl, Andreas
dc.contributor.author
Francis, Roland
dc.contributor.author
Föhre, Bettina
dc.contributor.author
Lojewski, Christian
dc.contributor.author
Pratschke, Johann
dc.contributor.author
Thuss-Patience, Peter
dc.contributor.author
Modest, Dominik
dc.contributor.author
Rau, Beate
dc.contributor.author
Feldbrügge, Linda
dc.date.accessioned
2023-06-26T15:12:36Z
dc.date.available
2023-06-26T15:12:36Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/39902
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-39624
dc.description.abstract
Background: Cytoreductive surgery (CRS) in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) represents a multimodal treatment concept for patients with peritoneal surface malignancies. The use of intraperitoneal cisplatin (CDDP) is associated with a risk of acute kidney injury (AKI). The aim of this study is to evaluate the protective effect of perioperative sodium thiosulfate (STS) administration on kidney function in patients undergoing CRS and CDDP-based HIPEC.
Patients and Methods: We retrospectively analyzed clinical data of all patients who underwent CRS and CDDP-based HIPEC at our hospital between March 2017 and August 2020. Patients were stratified according to the use of sodium thiosulfate (STS vs. no STS). We compared kidney function and clinical outcome parameters between both groups and determined risk factors for postoperative AKI on univariate and multivariate analysis. AKI was classified according to acute kidney injury network (AKIN) criteria.
Results: Of 238 patients who underwent CRS and CDDP-based HIPEC, 46 patients received STS and 192 patients did not. There were no significant differences in baseline characteristics. In patients who received STS, a lower incidence (6.5% vs. 30.7%; p = 0.001) and severity of AKI (p = 0.009) were observed. On multivariate analysis, the use of STS (OR 0.089, p = 0.001) remained an independent kidney-protective factor, while arterial hypertension (OR 5.283, p < 0.001) and elevated preoperative urea serum level (OR 5.278, p = 0.032) were predictors for postoperative AKI.
Conclusions: The present data suggest that STS protects patients from AKI caused by CRS and CDDP-based HIPEC. Further prospective studies are needed to validate the benefit of STS among kidney-protective strategies.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
sodium thiosulfate
en
dc.subject
Acute Kidney Injury
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Sodium Thiosulfate Reduces Acute Kidney Injury in Patients Undergoing Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy with Cisplatin: A Single-Center Observational Study
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1245/s10434-021-10508-x
dcterms.bibliographicCitation.journaltitle
Annals of Surgical Oncology
dcterms.bibliographicCitation.number
1
dcterms.bibliographicCitation.originalpublishername
Springer Nature
dcterms.bibliographicCitation.pagestart
152
dcterms.bibliographicCitation.pageend
162
dcterms.bibliographicCitation.volume
29
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
34350529
dcterms.isPartOf.issn
1068-9265
dcterms.isPartOf.eissn
1534-4681